greeksoup/ stock research
Stock research / United States / TAK / Year to 31 March 2019

Takeda Pharmaceutical Company Limited (TAK) annual results, year to 31 March 2019: revenue JPY 2,097 billion, from the 20-F

Takeda Pharmaceutical Company Limited files a 20-F with the SEC once a year, in yen. In the year to 31 March 2019 it reported revenue of JPY 2,097 billion ($18.9 billion at the year's average rate), up 18.5% on the year before. Its profit attributable to shareholders was JPY 135 billion, down 27.7%, and diluted earnings per share JPY 139.82.

Revenue
JPY 2,097 billion
+18.5% on the year
FY2017FY2019
Operating margin
11.3%
13.7% a year earlier
FY2017FY2019
Net income
JPY 135 billion
-27.7% on the year
FY2017FY2019
Diluted EPS
JPY 139.82
-41.1% on the year
FY2017FY2019

this yearthe year beforeIn yen as filed. Hover a bar for its figure.

Income statement (profit and loss)

Year toMar 2018Mar 2019 †
Revenue1,7712,097
Cost of sales496652
Research and development325368
Operating profit242238
Finance costs31.983.3
Profit before tax217128
Income tax30.5-7.5
Profit for the year187135
Profit attributable to shareholders187135
Filing20-F20-F
JPY billion, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed.
Read moreA line the company does not file under the standard tag is left out rather than estimated.
Year toMar 2018Mar 2019 †
Diluted EPS237.56139.82
Basic EPS239.35140.61
Filing20-F20-F

JPY per ordinary share, as filed.

Cash flow

Year toMar 2018Mar 2019 †
Cash from operations378328
Purchase of property, plant and equipment67.077.7
Free cash flow311251
Cash from investing-93.3-2,836
Cash from financing-3262,946
Depreciation and amortisation182248
Buybacks18.81.2
Dividends paid142143
Filing20-F20-F

JPY billion. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.

Balance sheet

Year toMar 2018Mar 2019 †
Funded by
Equity attributable to shareholders1,9975,182
Non-controlling interests20.04.0
Borrowings, as filed9865,751
Lease liabilitiesn/a0.0
Other liabilities1,1032,856
Total equity and liabilities4,10613,793
Owned
Property, plant and equipment5371,332
Goodwill1,0294,240
Other intangible assets1,0144,751
Cash and cash equivalents295702
Trade and other receivables420742
Inventories213920
Other assets5981,106
Total assets4,10613,793
Filing20-F20-F

JPY billion, at each fiscal year end.

Ratios on the filed lines

Year toMar 2018Mar 2019 †
Operating margin13.7%11.3%
Net margin10.6%6.4%
Free cash flow margin17.6%12.0%
Return on year-end equity9.4%2.6%
Effective tax rate14.0%-5.9%
Filing20-F20-F

Arithmetic on the filed lines of the same year.

20-F for the year to 31 March 2019, filed 29 June 2021: the filing. The figures are in yen as filed.